Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors.
We show here that colon-carcinoma cell lines adhere to E-selectin via sialyl Lewis x and sialyl Lewis a (s(Lex) and s(Lea)) oligosaccharides and that this adhesion can be enhanced by TNF stimulation. To study in greater detail this endothelial binding, we analysed the mRNA expression and function of the enzymes participating in the generation of s(Lex) and s(Lea on cancer cells. These oligosaccharides are synthesized by sequential action of alpha 2,3 sialyl (alpha 2,3-ST) and alpha 1,3/1/4 fucosyltransferases (alpha 1,3/1,4-FT) on existing (poly)N-acetyllactosamine chains. We report here that mRNAs of 2 recently cloned alpha 2,3-STs and 4 alpha 1,3/1,4-FTs are expressed in adenocarcinoma cells. In functional assays alpha 2,3-ST and alpha 1,3- or 1,4-FT activities were observed in adenocarcinoma cell lysates to exogenous N-acetyllactosamine and lacto-N-biose acceptors and to their sialylated derivatives, leading to the synthesis of the sialyl-N-acetyllactosamine and s(Lex) or the sialyllacto-N-biose and s(Lea), respectively. Furthermore, the inflammatory cytokine TNF could enhance some alpha 2,3-ST and alpha 1,3/1,4-FT activities capable of generating E-selectin counter-receptors. Taken together, these data show that COLO 205 and HT-29 adenocarcinoma cell lines adhere to E-selectin in a TNF-inducible manner via their cell-surface s(Lex) and s(Lea). These cells also express mRNA as well as inducible enzyme activities of several alpha 2,3-STs and alpha 1,3/1,4-FTs responsible for the final steps in the synthesis of s(Lex) and s(Lea).(ABSTRACT TRUNCATED AT 250 WORDS)
Majuri
M L
ML
Department of Bacteriology and Immunology, Haartman Institute, Helsinki, Finland.
Niemelä
R
R
Tiisala
S
S
Renkonen
O
O
Renkonen
R
R
D000230:Adenocarcinoma / Q000201:enzymology* / Q000378:metabolism / Q000648:ultrastructure; D000906:Antibodies / Q000378:metabolism; D018395:CA-19-9 Antigen; D002240:Carbohydrate Sequence; D002448:Cell Adhesion / Q000502:physiology; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000378:metabolism / Q000648:ultrastructure; D019040:E-Selectin / Q000096:biosynthesis*; D000939:Epitopes / Q000378:metabolism; D005647:Fucosyltransferases / Q000235:genetics / Q000378:metabolism*; D005732:Gangliosides / Q000096:biosynthesis; D019073:HT29 Cells / Q000201:enzymology; D006801:Humans; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000096:biosynthesis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D000080506:Sialyl Lewis X Antigen; D012799:Sialyltransferases / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase
D000906:Antibodies; D018395:CA-19-9 Antigen; D019040:E-Selectin; D000939:Epitopes; D005732:Gangliosides; D009844:Oligosaccharides; D012333:RNA, Messenger; D000080506:Sialyl Lewis X Antigen; D014409:Tumor Necrosis Factor-alpha; C064564:sialyl Le(a) ganglioside; D005647:Fucosyltransferases; C031692:galactoside 3-fucosyltransferase; C019818:3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase; D012799:Sialyltransferases; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase; C000722087:ST3GAL1 protein, human